{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:02:40Z","timestamp":1775833360829,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-025-00769-8","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:19:49Z","timestamp":1770106789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies"],"prefix":"10.1007","volume":"21","author":[{"given":"Talia","family":"Zahra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bambace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyle","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charbel","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Kadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Lezcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenlys","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiba","family":"Al-Sagheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"769_CR1","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. JNCI J Natl Cancer Inst. 1960;25(1):85\u2013109.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"5405","key":"769_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290\u20133.","journal-title":"Nature"},{"issue":"4944","key":"769_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824\u201330.","journal-title":"Science"},{"issue":"7","key":"769_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/cncr.11664","volume":"98","author":"S Faderl","year":"2003","unstructured":"Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98(7):1337\u201354.","journal-title":"Cancer"},{"issue":"3","key":"769_CR5","first-page":"196","volume":"5","author":"LM Secker-Walker","year":"1991","unstructured":"Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5(3):196\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"769_CR6","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396\u2013407.","journal-title":"Blood"},{"issue":"19","key":"769_CR7","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII\/ECOG2993. Blood. 2009;113(19):4489\u201396.","journal-title":"Blood"},{"issue":"3","key":"769_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863\u201371.","journal-title":"Blood"},{"issue":"20","key":"769_CR9","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075\u201386.","journal-title":"J Clin Oncol"},{"issue":"17","key":"769_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613\u201323.","journal-title":"N Engl J Med"},{"issue":"15","key":"769_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547\u201355.","journal-title":"Lancet Oncol"},{"issue":"36","key":"769_CR12","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42(36):4246\u201351.","journal-title":"J Clin Oncol"},{"issue":"7","key":"769_CR13","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357\u201366.","journal-title":"Blood"},{"issue":"6","key":"769_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843\u201350.","journal-title":"Blood"},{"issue":"4","key":"769_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2006","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal Fo, Delabesse E, Witz F, Maury Sb, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2006;109(4):1408\u201313.","journal-title":"Blood"},{"issue":"7","key":"769_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","volume":"28","author":"KR Schultz","year":"2014","unstructured":"Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children\u2019s oncology group study AALL0031. Leukemia. 2014;28(7):1467\u201371.","journal-title":"Leukemia"},{"issue":"9","key":"769_CR17","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome\u2013positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676\u20138.","journal-title":"Blood"},{"issue":"4","key":"769_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","volume":"112","author":"K Porkka","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lund\u00e1n T, Rimpil\u00e4inen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia. Blood. 2008;112(4):1005\u201312.","journal-title":"Blood"},{"issue":"3","key":"769_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM, Forman SJ, Ha CS, Wong JYC, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250\u20139.","journal-title":"Blood Adv"},{"issue":"6","key":"769_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774\u201382.","journal-title":"Blood"},{"issue":"25","key":"769_CR21","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Fo\u00e0","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521\u20138.","journal-title":"Blood"},{"issue":"6","key":"769_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","volume":"126","author":"D-Y Kim","year":"2015","unstructured":"Kim D-Y, Joo Y-D, Lim S-N, Kim S-D, Lee J-H, Lee J-H, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746\u201356.","journal-title":"Blood"},{"issue":"23","key":"769_CR23","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1182\/blood.2023023502","volume":"143","author":"Y Chalandon","year":"2024","unstructured":"Chalandon Y, Rousselot P, Chevret S, Cayuela J-M, Kim R, Huguet F, et al. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood. 2024;143(23):2363\u201372.","journal-title":"Blood"},{"issue":"3","key":"769_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","volume":"6","author":"S Shen","year":"2020","unstructured":"Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358\u201366.","journal-title":"JAMA Oncol"},{"issue":"21","key":"769_CR25","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"4","key":"769_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404.","journal-title":"Blood"},{"key":"769_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"G Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Rambaldi A, et al. Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107\u201314.","journal-title":"Eur J Cancer"},{"issue":"8","key":"769_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"769_CR29","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"key":"769_CR30","unstructured":"BLINCYTO (blinatumomab) [package insert]. Silver Spring (MD): U.S. Food and drug administration. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125557s008lbl.pdf. Accessed 15 Dec 2025."},{"issue":"6","key":"769_CR31","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nm1253","volume":"11","author":"A Castor","year":"2005","unstructured":"Castor A, Nilsson L, Astrand-Grundstr\u00f6m I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11(6):630\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"769_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","volume":"482","author":"AS Duffield","year":"2023","unstructured":"Duffield AS, Mullighan CG, Borowitz MJ. International consensus classification of acute lymphoblastic leukemia\/lymphoma. Virchows Arch. 2023;482(1):11\u201326.","journal-title":"Virchows Arch"},{"issue":"14","key":"769_CR33","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2023021752","volume":"143","author":"L Bastian","year":"2024","unstructured":"Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, et al. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL. Blood. 2024;143(14):1391\u20138.","journal-title":"Blood"},{"issue":"7","key":"769_CR34","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","volume":"55","author":"JC Kim","year":"2023","unstructured":"Kim JC, Chan-Seng-Yue M, Ge S, Zeng AGX, Ng K, Gan OI, et al. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. Nat Genet. 2023;55(7):1186\u201397.","journal-title":"Nat Genet"},{"issue":"20","key":"769_CR35","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","volume":"129","author":"L Hovorkova","year":"2017","unstructured":"Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017;129(20):2771\u201381.","journal-title":"Blood"},{"issue":"31","key":"769_CR36","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"769_CR37","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A, et al. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021;106(7):1828\u201338.","journal-title":"Haematologica"},{"issue":"5","key":"769_CR38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","volume":"36","author":"Y Sasaki","year":"2022","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36(5):1253\u201360.","journal-title":"Leukemia"},{"issue":"2","key":"769_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3324\/haematol.2018.196055","volume":"104","author":"AL Fedullo","year":"2019","unstructured":"Fedullo AL, Messina M, Elia L, Piciocchi A, Gianfelici V, Lauretti A, et al. Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2019;104(2):312\u20138.","journal-title":"Haematologica"},{"issue":"1","key":"769_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/10428194.2017.1326596","volume":"59","author":"C Motll\u00f3","year":"2018","unstructured":"Motll\u00f3 C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(1):146\u201354.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"769_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.leu.2403324","volume":"18","author":"NA Heerema","year":"2004","unstructured":"Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, Janka-Schaub G, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18(4):693\u2013702.","journal-title":"Leukemia"},{"issue":"3","key":"769_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24625","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, et al. Poor outcomes associated with +der(22)t(9;22) and -9\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92(3):238\u201343.","journal-title":"Am J Hematol"},{"issue":"2","key":"769_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3324\/haematol.11891","volume":"93","author":"M Yanada","year":"2008","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica. 2008;93(2):287\u201390.","journal-title":"Haematologica"},{"issue":"13","key":"769_CR44","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2017-07-796862","volume":"131","author":"H Pfeifer","year":"2018","unstructured":"Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obl\u00e4nder J, et al. Genomic CDKN2A\/2B deletions in adult Ph(+) ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018;131(13):1464\u201375.","journal-title":"Blood"},{"issue":"2\u20133","key":"769_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1005963732481","volume":"38","author":"N G\u00f6kbuget","year":"1998","unstructured":"G\u00f6kbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neurooncol. 1998;38(2\u20133):167\u201380.","journal-title":"J Neurooncol"},{"issue":"2","key":"769_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","volume":"108","author":"HM Lazarus","year":"2006","unstructured":"Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993. Blood. 2006;108(2):465\u201372.","journal-title":"Blood"},{"issue":"5","key":"769_CR47","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/blood.V72.5.1784.1784","volume":"72","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988;72(5):1784\u20139.","journal-title":"Blood"},{"issue":"7","key":"769_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00277-017-3002-1","volume":"96","author":"R Sanchez","year":"2017","unstructured":"Sanchez R, Ayala R, Alonso RA, Mart\u00ednez MP, Ribera J, Garc\u00eda O, et al. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Ann Hematol. 2017;96(7):1069\u201375.","journal-title":"Ann Hematol"},{"issue":"11","key":"769_CR49","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.leukres.2008.04.011","volume":"32","author":"O Reman","year":"2008","unstructured":"Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and\/or at first relapse: results from the GET-LALA group. Leuk Res. 2008;32(11):1741\u201350.","journal-title":"Leuk Res"},{"issue":"1","key":"769_CR50","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.26622","volume":"98","author":"S Paul","year":"2023","unstructured":"Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, et al. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023;98(1):E11\u20134.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"769_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2024-206602","volume":"144","author":"NJ Short","year":"2024","unstructured":"Short NJ, Kantarjian H, Jain N, Takahashi K, Furudate K, Senapati J, et al. Blinatumomab and ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse. Blood. 2024;144(Supplement 1):837.","journal-title":"Blood"},{"issue":"Supplement 1","key":"769_CR52","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1182\/blood-2023-189632","volume":"142","author":"S Chiaretti","year":"2023","unstructured":"Chiaretti S, Leoncin M, Elia L, Piciocchi A, Matarazzo M, Di Trani M, et al. Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALLL2820 trial. Blood. 2023;142(Supplement 1):4249\u20134249.","journal-title":"Blood"},{"issue":"Supplement 1","key":"769_CR53","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","volume":"144","author":"S Chiaretti","year":"2024","unstructured":"Chiaretti S, Leoncin M, Elia L, Soddu S, Piciocchi A, Matarazzo M, et al. Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the Gimema ALL2820. Blood. 2024;144(Supplement 1):835.","journal-title":"Blood"},{"issue":"23","key":"769_CR54","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139(23):3376\u201386.","journal-title":"Blood"},{"issue":"24","key":"769_CR55","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711\u20139.","journal-title":"Blood"},{"issue":"4","key":"769_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504\u20137.","journal-title":"Blood"},{"issue":"20","key":"769_CR57","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140(20):2101\u201312.","journal-title":"Blood"},{"issue":"15","key":"769_CR58","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.33529","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127(15):2648\u201356.","journal-title":"Cancer"},{"issue":"12","key":"769_CR59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"769_CR60","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1002\/hem3.67","volume":"8","author":"JM Ribera","year":"2024","unstructured":"Ribera JM, Morgades M, Ribera J, Montesinos P, Cano-Ferri I, Martinez P, et al. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: long-term results. Hemasphere. 2024;8(4):e67.","journal-title":"Hemasphere"},{"issue":"12","key":"769_CR61","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/ajh.27475","volume":"99","author":"T Badar","year":"2024","unstructured":"Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, et al. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a multi-institutional study. Am J Hematol. 2024;99(12):2388\u201391.","journal-title":"Am J Hematol"},{"issue":"25","key":"769_CR62","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"769_CR63","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"769_CR64","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European group for blood and marrow transplantation. Blood. 2010;116(22):4439\u201343.","journal-title":"Blood"},{"issue":"1","key":"769_CR65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","volume":"6","author":"MJ Wieduwilt","year":"2022","unstructured":"Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6(1):339\u201357.","journal-title":"Blood Adv"},{"issue":"11","key":"769_CR66","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3109\/10428194.2013.779691","volume":"54","author":"C Eroglu","year":"2013","unstructured":"Eroglu C, Pala C, Kaynar L, Yaray K, Aksozen MT, Bankir M, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54(11):2474\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"769_CR67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/hematology.2021000257","volume":"2021","author":"RJ Lin","year":"2021","unstructured":"Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematol Am Soc Hematol Educ Program. 2021;2021(1):254\u201363.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"769_CR68","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41409-025-02630-1","volume":"60","author":"N Moukalled","year":"2025","unstructured":"Moukalled N, Ferhat AT, Bazarbachi A, Blaise D, Broers AEC, Castilla-Llorente C, et al. Improved outcomes over time in patients aged >\/=60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party. Bone Marrow Transplant. 2025;60(8):1160\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"769_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35773","volume":"131","author":"E Kugler","year":"2025","unstructured":"Kugler E, Kantarjian H, Jabbour E, Khaire N, Short NJ, Kadia TM, et al. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2025;131(5):e35773.","journal-title":"Cancer"},{"issue":"3","key":"769_CR70","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000510112","volume":"144","author":"B Samra","year":"2021","unstructured":"Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O\u2019Brien S, et al. Discontinuation of maintenance tyrosine kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia outside of transplant. Acta Haematol. 2021;144(3):285\u201392.","journal-title":"Acta Haematol"},{"issue":"5","key":"769_CR71","first-page":"1177","volume":"110","author":"M Dragani","year":"2025","unstructured":"Dragani M, Ansuinelli M, Papayannidis C, Fracchiolla N, Cardinali V, Cedrone M, et al. Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a campus ALL real-life study. Haematologica. 2025;110(5):1177\u201381.","journal-title":"Haematologica"},{"issue":"7647","key":"769_CR72","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"18","key":"769_CR73","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1182\/bloodadvances.2025016665","volume":"9","author":"M Chanut","year":"2025","unstructured":"Chanut M, Cabannes-Hamy A, Balsat M, Sahki N, Raffoux E, Hicheri Y, et al. Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2025;9(18):4580\u20134.","journal-title":"Blood Adv"},{"key":"769_CR74","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood-2023-174246","volume":"1","author":"MR Luskin","year":"2023","unstructured":"Luskin MR, Murakami MA, Keating J, Winer ES, Garcia JS, Stahl M, et al. A Phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR-ABL1-positive ALL and blast phase CML in adults. Blood. 2023;1:965 S.","journal-title":"Blood"},{"key":"769_CR75","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1200\/JCO.2025.43.16_suppl.6509","volume":"1","author":"MR Luskin","year":"2025","unstructured":"Luskin MR, Murakami MA, Keating JH, Wang ES, McMasters M, Flamand Y, et al. A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR::ABL1-positive acute lymphoblastic leukemia and blast phase chronic myeloid leukemia in adults. J Clin Oncol. 2025;1:6509.","journal-title":"J Clin Oncol"},{"key":"769_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546371","volume":"16","author":"Z Wen","year":"2025","unstructured":"Wen Z, Liu Z, Ye X, Fan Z, Lin R, Huang F, et al. Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study. Front Immunol. 2025;16:1546371.","journal-title":"Front Immunol"},{"issue":"6","key":"769_CR77","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/bjh.19804","volume":"205","author":"W Liu","year":"2024","unstructured":"Liu W, Wang C, Ouyang W, Hao J, Ren J, Peng L, et al. Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed\/refractory disease. Br J Haematol. 2024;205(6):2228\u201333.","journal-title":"Br J Haematol"},{"issue":"11","key":"769_CR78","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1007\/s00277-024-06027-w","volume":"103","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Huang J, Wang Y, Han Y, Xue S, Yang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2024;103(11):4643\u20138.","journal-title":"Ann Hematol"},{"issue":"7","key":"769_CR79","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","volume":"12","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial. Lancet Haematol. 2025;12(7):e529\u201341.","journal-title":"Lancet Haematol"},{"key":"769_CR80","first-page":"S4159194","volume":"25","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Yoon JH, Barba P, Torres Mi\u00f1ana L, Wu D, Shin DY, Teng CL, Borthakur G, Yao M, Papayannidis C, Castleton A, Shah B, Fleming S, Ahmed M, Lesley R, Liu Y, Olabode D, Wey M, Andrade M, Goekbuget N, Kantarjian H, Topp MS. Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: early results from the Phase I\/II SYRUS study. EHA Congress. 2025;25:S4159194.","journal-title":"EHA Congress"},{"issue":"6","key":"769_CR81","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, DeAngelo DJ, G\u00f6kbuget N, Advani AS, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905\u201313.","journal-title":"Cancer"},{"issue":"8","key":"769_CR82","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajh.26238","volume":"96","author":"N Jain","year":"2021","unstructured":"Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96(8):1000\u20137.","journal-title":"Am J Hematol"},{"issue":"8","key":"769_CR83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17474086.2025.2523551","volume":"18","author":"JA Yared","year":"2025","unstructured":"Yared JA, Fromowitz A, Kocoglu M, Hardy N, Atanackovic D, Rapoport AP. Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion? Expert Rev Hematol. 2025;18(8):585\u201393.","journal-title":"Expert Rev Hematol"},{"issue":"23","key":"769_CR84","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330.","journal-title":"N Engl J Med"},{"issue":"5","key":"769_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"10299","key":"769_CR86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"issue":"6","key":"769_CR87","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","volume":"11","author":"M Zhang","year":"2025","unstructured":"Zhang M, Fu S, Feng J, Hong R, Wei G, Zhao H, et al. Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a nonrandomized clinical trial. JAMA Oncol. 2025;11(6):625\u20139.","journal-title":"JAMA Oncol"},{"issue":"6","key":"769_CR88","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/10428194.2025.2449582","volume":"66","author":"J Senapati","year":"2025","unstructured":"Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, et al. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma. 2025;66(6):989\u20131000.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"769_CR89","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"769_CR90","unstructured":"TECARTUS (brexucabtagene autoleucel) [package insert]. Silver Spring (MD): U.S. Food and drug administration. 2021. Available from:\u00a0https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/tecartus\/tecartus-pi.pdf. Accessed 15 Dec 2025."},{"key":"769_CR91","unstructured":"KYMRIAH (tisagenlecleucel) [package insert]. Silver Spring (MD): U.S. Food and drug administration. n.d. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kymriah.pdf. Accessed 15 Dec 2025."},{"key":"769_CR92","unstructured":"AUCATZYL (obecabtagene autoleucel, obe-cel) [package insert]. Silver Spring (MD): U.S. Food and drug administration. n.d. Available from: https:\/\/www.autolus.com\/media\/1sdfadp0\/obe-cel-us-prescribing-information-and-medication-guide.pdf. Accessed 15 Dec 2025."},{"issue":"2","key":"769_CR93","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024;143(2):118\u201323.","journal-title":"Blood"},{"issue":"1","key":"769_CR94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","volume":"13","author":"J Niu","year":"2023","unstructured":"Niu J, Qiu H, Xiang F, Zhu L, Yang J, Huang C, et al. CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J. 2023;13(1):44.","journal-title":"Blood Cancer J"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00769-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:04:28Z","timestamp":1770113068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00769-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00769-8","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"TZ reports no conflict of interest.NB reports no conflict of interest.LF reports no conflict of interest.CEC reports no conflict of interest.MAL reports no conflict of interest.YK reports no conflict of interest.YV reports no conflict of interest.TAS reports no conflict of interest.FEC reports Consultant: SPD Oncology, Amgen, CTI BioPharma, AbbVie, MorphoSys, PharmaEssentia, BMS, Geron, Sobi, DAVA Oncology, Taiho Oncology, Daiichi Sankyo, Syndax, Novartis, Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"2"}}